Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
-
Wierda, W. G. (University of Texas.)
;
Allan, J. N. (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, Thomas J (University of California San Diego. Moores Cancer Center) ;
Opat, S. (Monash University) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Badoux, X. C. (Ministry of Health) ;
Kuss, B. J. (Flinders University. Medical Centre) ;
Jackson, Sharon (Middlemore Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Jacobs, R. M. D. (Levine Cancer Institute) ;
Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ;
Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ;
Pak, Y. (Pharmacyclics LLC. AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. AbbVie Company) ;
Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ;
Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ;
Dean, James P (Pharmacyclics LLC. AbbVie Company) ;
James, D. F. (Pharmacyclics LLC. AbbVie Company) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ;
Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona